Targacept
Latest round
- Series B
Last raised
- Mar 2003
Total raised
- $90M
Investors
- 19
About Targacept
Founded in 1997 in Winston-Salem, US, Targacept specializes in pharmaceutical development, particularly for central nervous system disorders.Targacept focuses on developing innovative pharmaceutical products aimed at addressing unmet medical needs, particularly in the field of central nervous system disorders. Their core offerings include a range of compounds that target specific receptors to modulate neuronal activity, providing potential therapeutic options for conditions such as depression and cognitive impairment. These products are designed to enhance the efficacy of existing treatments while minimizing side effects, thereby improving patient outcomes. Targacept primarily serves healthcare professionals, hospitals, and specialty pharmacies, catering to patients across North America and Europe who require advanced treatment options for complex neurological conditions.In 2014, Targacept reported a revenue of USD 275,000, with an EBITDA loss of USD 28,588,000. The company's revenue model is based on collaboration agreements and licensing deals that allow them to monetize their proprietary research and development efforts.Targacept's future growth strategy includes the introduction of new products from its pipeline, with specific launch dates yet to be confirmed. The company plans to expand into new geographic markets, focusing on regions in North America and Europe, leveraging the insights gained from its merger with Catalyst Biosciences.
Who invested in Targacept
19 investors across 3 rounds
See all investors in Targacept
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Targacept
Who invested in Targacept?
Targacept has 19 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Targacept raised?
Targacept has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Targacept last raise money?
Targacept's most recent round on record is a Series B, in Mar 2003.
What does Targacept do?
Founded in 1997 in Winston-Salem, US, Targacept specializes in pharmaceutical development, particularly for central nervous system disorders.
Where is Targacept headquartered?
Targacept is headquartered in Winston-Salem, US.
Which VCs invest in companies like Targacept?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Targacept's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Targacept? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.